- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01817842
Study of Mobile Phone Support for the DC Tobacco Quitline
Comparative Effectiveness of Web-based Mobile Support for the DC Tobacco Quitline
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study aims to bolster the effectiveness of the Washington D.C. Quitline (DCQL) program with the addition of a web-based mobile EX (mEX) cessation support system. This mEX system is designed to fill the gaps between quitline calls with ready access to a menu of evidenced-based treatment components, while also providing DCQL counselors with detailed information about their clients' ongoing progress with cessation - two developments that constitute a major advance over standard quitline programming. With the addition of mEX, DCQL counselors will be able to tailor their advice from the outset of each call and even identify counterproductive patterns that would have otherwise gone unnoticed. This innovative extension of our previous work leverages our expertise with ecological assessment methodology and behavioral informatics for the purpose of dynamic relapse prevention support within the context of an underserved community QL.
The project is an additive two-group randomized controlled trial to test whether the addition of mEX improves abstinence rates at 1-, 3-, 6-, and 9-months relative to standard care provided by DCQL. Participants will be 700 smokers who contact the DCQL and are randomized to receive either standard DCQL programming (N=300) or DCQL plus MQE (N=400). Participants assigned to standard DCQL programming will receive 6 proactive QL counseling sessions and free nicotine replacement therapy (NRT). Participants assigned to DCQL plus MQE will also receive mobile access to the MQE system via a web-enabled cellular telephone provided by the study. Relative to usual care, we expect that MQE will improve outcomes by improving delivery, utilization and thereby effectiveness of DCQL resources.
Specific Aim 1. Examine abstinence rates in DCQL participants receiving usual-care relative to those also receiving mobile quitline enhancement. Relative to usual-care controls, mobile quitline enhancement is expected to improve 7-day point prevalence abstinence rates at 1-, 3-, 6-, and 9-months.
Specific Aim 2. Examine treatment utilization in DCQL participants receiving usual-care relative to those also receiving mobile quitline enhancement. Relative to usual-care controls, mobile quitline enhancement is expected to improve utilization of available DCQL programming resources.
Specific Aim 3. Examine whether utilization of DCQL or mobile support services moderates their impact on outcomes. Treatment effects are expected to vary with the degree that they are utilized, such that greater utilization will predict improved abstinence rates at all time points.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20036
- United Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Active tobacco smoker of at least 5 cigarettes / day
- Read, speak and write English
- Access to a telephone at either home or work
- Contacts DC Tobacco Quitline and makes an attempt to quit smoking
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: mEX support
Participants in this arm receive both standard DC Quitline Support and Mobile EX cessation support.
Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts.
Participants receive summary information and graphics that help them understand what is working best for them.
Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
|
Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts.
Participants receive summary information and graphics that help them understand what is working best for them.
Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
Other Names:
Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
|
|
ACTIVE_COMPARATOR: Device Control
Participants randomized to this arm receive standard DC Quitline Support plus the device control.
Device control includes an identical device (i.e., mobile phone) to that provided to the intervention group, but participants do not receive any of the phone-based mEX support features.
Those in the device control group receive their device at the 1-month time point - a design feature that allows a direct comparison of the mEX intervention to standard quitline services over the first month.
|
Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
Mobile phone for use during cessation attempt but with no mEX support components
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Smoking Abstinence
Time Frame: 9-months
|
Point-prevalent abstinence from smoking cigarettes over the past 7-days.
Verified with expired carbon monoxide at 1-month.
Reported by participants at 3-, 6- and 9-months.
|
9-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Daily Lapse Status
Time Frame: Month 1
|
Daily abstinence versus any smoking (i.e., lapse) status among those who are actively trying to abstain (i.e., not those who have completely relapsed).
|
Month 1
|
|
Quitline utilization
Time Frame: Month 1
|
Participant receipt and initiation of support calls from DC Quitline staff.
|
Month 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas R Kirchner, PhD, Truth Initiative
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RC1DA028710 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
National University of SingaporeRecruitingSmoking &Amp; Tobacco CessationSingapore
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedSmoking &Amp; Tobacco CessationUnited States
-
Sultan Qaboos UniversityCompletedSmoking Cessation | Tobacco Use Cessation | Smoking PreventionOman
-
The University of Hong KongCompletedSmoking Cessation Counseling Ability | Smoking Cessation Counseling PracticeHong Kong
Clinical Trials on Mobile EX cessation support
-
Oulu University HospitalActive, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnCurrent Smoker | Malignant Neoplasm | Current Every Day Smoker | Cigarette SmokerUnited States
-
Vejle HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsActive, not recruiting
-
Pontificia Universidad Catolica de ChileCompletedSmoking CessationChile
-
Recep Tayyip Erdogan University Training and Research...Turkish Thoracic SocietyRecruitingTobacco Cessation | Bronchiectasis Adult | Asthma COPDTurkey
-
University of ManitobaGovenment of Manitoba; Canadian Foundation for Pharmacy; Neighbourhood Pharmacy...Completed
-
University of GuamNational Cancer Institute (NCI); University of Hawaii Cancer Research CenterCompletedTobacco Cessation | Betel Nut ChewerGuam
-
The University of Hong KongNorth District Hospital; Queen Mary Hospital, Hong Kong; Pamela Youde Nethersole... and other collaboratorsUnknownSelf Inflicted Injury | Suicide and Self Inflicted InjuryHong Kong
-
University of WaterlooOttawa Heart Institute Research Corporation; Canadian Tobacco Control Research...CompletedSmoking Cessation
-
McGill University Health Centre/Research Institute...Canadian Institutes of Health Research (CIHR); Greybox Solutions Inc.Completed